Cost-effectiveness of cancer drugs: Comparative analysis of the United States and England
England’s National Institute for Health and Care Excellence (NICE) and the USβ Institute for Clinical and Economic Review (ICER) both conduct cost-effectiveness evaluations for new cancer drugs to help payers make drug coverage decisions. However, NICE and ICER assessments have been noted to reach different conclusions. We aim to better understand the degree to which their recommendations diverge…